Retrospective Evaluation Of Weekly Docetaxel In Recurrent Ovarian Cancer: A Single Center Experience

10.5580/1829 ◽  
2006 ◽  
Vol 6 (1) ◽  
Keyword(s):  
Ovarian Cancer ◽  
Recurrent Ovarian Cancer ◽  
Retrospective Evaluation ◽  
Single Center ◽  
Weekly Docetaxel ◽  
Single Center Experience

Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience

Chemotherapy ◽  
2016 ◽  
Vol 61 (3) ◽  
pp. 122-126 ◽  
Author(s):  
Guillaume Moriceau ◽  
Romain Rivoirard ◽  
Benoîte Méry ◽  
Alexis Vallard ◽  
Cécile Pacaut ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Liposomal Doxorubicin ◽  
Performance Status ◽  
Real Life ◽  
Pegylated Liposomal Doxorubicin ◽  
Progression Free Survival ◽  
Recurrent Ovarian Cancer ◽  
Single Center ◽  
Disease Response ◽  
Single Center Experience

Background: Trabectedin plus pegylated liposomal doxorubicin (PLD) proved efficacious as second-line treatment for patients with recurrent ovarian cancer (ROC). Methods: We report a single-center retrospective analysis of the efficacy and tolerance of trabectedin 1.1 mg/m2 every 3 weeks in a cohort of real-life ROC patients. Results: From February 2012 to January 2014, 17 patients were treated with trabectedin alone or combined with PLD. Median age was 61 years (range: 48-78). Performance status was 0-1 in 16 patients (94%). Disease response rate was 53% and disease control rate was 76%. At the end of the follow-up, 8 patients (47%) were alive. Median overall survival was 17.6 months (95% CI 13.6 to not reached). Median progression-free survival was 6.7 months (95% CI 5.4-10.0). The most frequent grade 3-4 toxicities were neutropenia (n = 4, 24%) and nausea/vomiting (n = 4, 24%). Conclusion: Trabectedin combined with PLD seems efficient in and well tolerated by real-life ROC patients.

Platinum-Pemetrexed Chemotherapy for Recurrent Ovarian Cancer (ROC): A Single Center Experience

2021 ◽  
pp. 1-9
Author(s):  
Anjana Joel ◽  
George John ◽  
Sherin Daniel ◽  
Vinotha Thomas ◽  
Ajit Sebastian ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Recurrent Ovarian Cancer ◽  
Single Center ◽  
Single Center Experience

Extraovarian conditions mimicking ovarian cancer: a single center experience of 15 years

2010 ◽  
Vol 284 (3) ◽  
pp. 713-719 ◽  
Author(s):  
Mustafa Ozat ◽  
Sunduz Ozlem Altinkaya ◽  
Tayfun Gungor ◽  
Mete Çağlar ◽  
Sema Zergeroglu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Single Center ◽  
Single Center Experience

Effective weekly docetaxel for recurrent ovarian cancer: A case report

2003 ◽  
Vol 13 (5) ◽  
pp. 683-686
Author(s):  
S. Komiyama ◽  
Y. Mizusawa ◽  
M. Onouchi ◽  
K. Takehara ◽  
A. Suzuki ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Progression Free Survival ◽  
Recurrent Ovarian Cancer ◽  
Salvage Chemotherapy ◽  
Stage Iiic ◽  
Serous Adenocarcinoma ◽  
Free Survival ◽  
Weekly Docetaxel ◽  
Docetaxel Treatment ◽  
Poorly Differentiated

We experienced a case of recurrent ovarian cancer that responded to weekly docetaxel. The patient had stage IIIC ovarian cancer (poorly differentiated serous adenocarcinoma). After initial remission was achieved by chemotherapy with paclitaxel and carboplatin plus cytoreductive surgery, the disease recurred and irinotecan therapy achieved temporary remission. During maintenance therapy with oral etoposide, the disease recurred again. We then tried five courses of weekly docetaxel therapy and it successfully controlled the disease. The progression-free survival time on weekly docetaxel treatment is now 7 months and the toxicity was extremely low. This patient demonstrates the effectiveness of weekly docetaxel as salvage chemotherapy for recurrent ovarian cancer.

Sign in / Sign up

Export Citation Format

Share Document